DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer
RNA-seq (gene expression) · human · 18 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 18 samples: 3 × BT474, Control, Day 0, vs 3 × BT474, DTP, Day 9, vs 3 × BT474, DTEP, Month 6, vs 3 × BT474, Resistant, Month 9,Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancerEMBO molecular medicine · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE231526_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA966201 and SRA study SRP435623. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 3 samples read as cases, 6 as controls.
How we read this: 4 replicated groups read from 18 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7287665 MDA-MB-453, Scrambled, Sample ID 1, rep1
- GSM7287666 MDA-MB-453, Scrambled, Sample ID 2, rep2
- GSM7287667 MDA-MB-453, Scrambled, Sample ID 4, rep3
- GSM7287668 MDA-MB-453, DUSP6 Knockdown, Sample ID 3, rep1
- GSM7287669 MDA-MB-453, DUSP6 Knockdown, Sample ID 5, rep2
- GSM7287670 MDA-MB-453, DUSP6 Knockdown, Sample ID 6, rep3
- GSM7287671 BT474, Control, Day 0, rep1 BT474, Control, Day 0,
- GSM7287672 BT474, Control, Day 0, rep2 BT474, Control, Day 0,
- GSM7287673 BT474, Control, Day 0, rep3 BT474, Control, Day 0,
- GSM7287674 BT474, DTP, Day 9, rep1 BT474, DTP, Day 9,
- GSM7287675 BT474, DTP, Day 9, rep2 BT474, DTP, Day 9,
- GSM7287676 BT474, DTP, Day 9, rep3 BT474, DTP, Day 9,
- GSM7287677 BT474, DTEP, Month 6, rep1 BT474, DTEP, Month 6,
- GSM7287678 BT474, DTEP, Month 6, rep2 BT474, DTEP, Month 6,
- GSM7287679 BT474, DTEP, Month 6, rep3 BT474, DTEP, Month 6,
- GSM7287680 BT474, Resistant, Month 9, rep1 BT474, Resistant, Month…
- GSM7287681 BT474, Resistant, Month 9, rep2 BT474, Resistant, Month…
- GSM7287682 BT474, Resistant, Month 9, rep3 BT474, Resistant, Month…
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing
- GSE231525 DUSP6 inhibition overcomes Neuregulin/HER3-driven therapy resistance in HER2+ breast cancer [BT474] 12 samples shares dusp6, her2, her3-driven, inhibition, neuregulin, overcomes, therapy
- GSE266219 Clinical and Immunological Responses to Combined JAK Inhibition and PD-1 immunotherapy for Lung Cancer Patients 79 samples shares inhibition, therapy
- GSE268776 Multi-omics approaches reveal that Diffuse Midline Gliomas are susceptible to replication stress therapy and cholesterol biosynthesis inhibition [RNA-seq] 64 samples shares inhibition, therapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.